{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:30:56Z","timestamp":1753878656586,"version":"3.41.2"},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Risk assessment on thrombocytopenia by selective serotonin reuptake inhibitors (SSRIs) or serotonin noradrenaline reuptake inhibitors (SNRIs) is limited. An observational study with cohort design was conducted based on the MID\u2010NET for evaluating the risk of thrombocytopenia by SSRIs and SNRIs in patients with depression compared to paroxetine. The exposure group was categorized as each drug of SSRIs\/SNRIs, SSRIs group (escitalopram, sertraline, fluvoxamine), SNRIs group (duloxetine, venlafaxine, milnacipran), or vortioxetine. We estimated the adjusted hazard ratio (aHR) of each drug compared to paroxetine for the risk of thrombocytopenia (platelet count &lt;\u2009100,000\/mm<jats:sup>3<\/jats:sup>). More severe definitions were used in sensitivity analyses. In all, 4759 patients (median age: 49\u2009years; 31.6% male) on SSRIs, 3440 patients (62\u2009years; 38.6% male) on SNRIs, 12 patients (42.5\u2009years; less than 83.4% male) on vortioxetine, and 2196 patients on paroxetine (62\u2009years; 33.2% male) were included for analysis. Compared with paroxetine, the aHRs (95% confidence interval) of SSRIs group and SNRIs group were 1.14 (0.76\u20131.70) and 0.77 (0.48\u20131.21), respectively. Among SSRIs, sertraline and fluvoxamine showed a relatively higher point estimate of aHR &gt;\u20091.0 (1.23 [95% confidence interval: 0.78\u20131.94] and 1.48 [0.87\u20132.51], respectively). The consistent results were also observed in the sensitivity analyses. The results suggest that the risk of thrombocytopenia by sertraline or fluvoxamine was comparable to that by paroxetine, known as having the risk of thrombocytopenia, leading to the revision of the sertraline package insert as a regulatory safety measure. Prescribers and clinicians may need to be vigilant to the possibility of sertraline\u2010induced thrombocytopenia in clinical practice.<\/jats:p>","DOI":"10.1111\/cts.70268","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T08:54:59Z","timestamp":1749200099000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk of Thrombocytopenia by <scp>SSRIs<\/scp> or <scp>SNRIs<\/scp> in Patients With Depression Based on <scp>MID<\/scp>\u2010<scp>NET<\/scp>: A Cohort Study in Japan"],"prefix":"10.1111","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3559-4350","authenticated-orcid":false,"given":"Yusuke","family":"Okada","sequence":"first","affiliation":[{"name":"Office of Pharmacovigilance I Pharmaceuticals and Medical Devices Agency  Tokyo Japan"},{"name":"Office of Pharmacovigilance II Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0570-2792","authenticated-orcid":false,"given":"Kazuhiro","family":"Kajiyama","sequence":"additional","affiliation":[{"name":"Office of Pharmacovigilance I Pharmaceuticals and Medical Devices Agency  Tokyo Japan"},{"name":"Office of Pharmacovigilance II Pharmaceuticals and Medical Devices Agency  Tokyo Japan"},{"name":"Office of Regulatory Science Research Center for Regulatory Science, Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maki","family":"Komamine","sequence":"additional","affiliation":[{"name":"Office of Pharmacovigilance I Pharmaceuticals and Medical Devices Agency  Tokyo Japan"},{"name":"Office of Pharmacovigilance II Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0654-5656","authenticated-orcid":false,"given":"Takashi","family":"Ando","sequence":"additional","affiliation":[{"name":"Office of Pharmacovigilance I Pharmaceuticals and Medical Devices Agency  Tokyo Japan"},{"name":"Office of Pharmacovigilance II Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8602-8295","authenticated-orcid":false,"given":"Tomoaki","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Office of Pharmacovigilance I Pharmaceuticals and Medical Devices Agency  Tokyo Japan"},{"name":"Office of Pharmacovigilance II Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1302-9430","authenticated-orcid":false,"given":"Chieko","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Office of Medical Informatics and Epidemiology Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Nonaka","sequence":"additional","affiliation":[{"name":"Office of Medical Informatics and Epidemiology Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Tsukuda","sequence":"additional","affiliation":[{"name":"Office of Pharmacovigilance II Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Office of Pharmacovigilance II Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Ueda","sequence":"additional","affiliation":[{"name":"Office of Pharmacovigilance II Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Horiuchi","sequence":"additional","affiliation":[{"name":"Office of Pharmacovigilance I Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyotaka","family":"Iguchi","sequence":"additional","affiliation":[{"name":"Office of Pharmacovigilance II Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0430-9887","authenticated-orcid":false,"given":"Yoshiaki","family":"Uyama","sequence":"additional","affiliation":[{"name":"Office of Medical Informatics and Epidemiology Pharmaceuticals and Medical Devices Agency  Tokyo Japan"},{"name":"Center for Regulatory Science Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"issue":"4","key":"e_1_2_11_2_1","first-page":"4","article-title":"Mechanism of Action of Antidepressant Medications","volume":"60","author":"Feighner J. P.","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"e_1_2_11_3_1","first-page":"5","article-title":"Basic Psychopharmacology of Antidepressants, Part 1: Antidepressants Have Seven Distinct Mechanisms of Action","volume":"59","author":"Stahl S. M.","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2007.9.1\/dhalperin"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7516.529"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196205032661802"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14227"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-757930"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2019-0380"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.50.3.297"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijh.ijh_47_20"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58050626"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2012.02355.x"},{"key":"e_1_2_11_14_1","unstructured":"Pharmaceuticals and Medical Devices Agency \u201cInformation Search for New Drugs Such as Review Reports Package Inserts and Other Related Infromation [in Japanese].\u201d(2023) https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuSearch\/."},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4879"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4777"},{"key":"e_1_2_11_17_1","unstructured":"Pharmaceuticals and Medical Devices Agency \u201cAct on the Pharmaceuticals and Medical Devices Agency (Act No.192 of 2002) [in Japanese].\u201d(2024) https:\/\/elaws.e\u2010gov.go.jp\/document?lawid=414AC0000000192."},{"key":"e_1_2_11_18_1","unstructured":"Pharmaceuticals and Medical Devices Agency \u201cPharmacoepidemiological Studies for Drug Safety Assessment Under MIHARI Framework [in Japanese]: Pharmaceuticals and Medical Devices Agency.\u201d(2024) https:\/\/www.pmda.go.jp\/safety\/surveillance\u2010analysis\/0045.html."},{"issue":"2","key":"e_1_2_11_19_1","first-page":"44","article-title":"Thrombocytopenia in Adults: Review Article","volume":"1","author":"Erkurt M. A.","year":"2012","journal-title":"Journal of Hematology"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.12703\/P6-45"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-2243"},{"key":"e_1_2_11_22_1","unstructured":"Ministry of Health Labour and Welfare \u201cManual for Management of Individual Serious Adverse Drug Reactions: Thrombocytopenia [in Japanese].\u201d(2022) https:\/\/www.pmda.go.jp\/files\/000245258.pdf."},{"key":"e_1_2_11_23_1","unstructured":"National Cancer Institute \u201cCommon Terminology Criteria for Adverse Events (CTCAE) Version 5.0 2017.\u201d(2024) https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"key":"e_1_2_11_24_1","article-title":"Alternative Approaches for Confounding Adjustment in Observational Studies Using Weighting Based on the Propensity Score: A Primer for Practitioners","volume":"367","author":"Rishi J. D.","year":"2019","journal-title":"BMJ"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.01.013"},{"key":"e_1_2_11_26_1","unstructured":"Ministry of Health Labour and Welfare \u201cOverview of 2020 Patient Survey [in Japanese].\u201d(2024) https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/kanja\/20\/index.html."},{"issue":"303","key":"e_1_2_11_27_1","first-page":"1","article-title":"Prevalence of Depression Among Adults Aged 20 and Over: United States, 2013\u20132016","author":"Brody D. J.","year":"2018","journal-title":"NCHS Data Brief"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00395-3"},{"key":"e_1_2_11_29_1","unstructured":"Ministry of Health Labour and Welfare \u201cRevision of PRECAUTIONS Sertraline hydrochloride.\u201d(2024) https:\/\/www.pmda.go.jp\/files\/000266127.pdf."}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70268","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T13:36:47Z","timestamp":1750945007000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/cts.70268"],"URL":"https:\/\/doi.org\/10.1111\/cts.70268","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"type":"print","value":"1752-8054"},{"type":"electronic","value":"1752-8062"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2025-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70268"}}